Skip to content

Oruka Therapeutics

US · ORKA #2003 by market cap Listed 1970
95.81 -1.76 -1.80%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 96.04 -1.57%
After-hours 95.81 0.00%
113.0855.0195.812026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ORKA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +123.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 9.8% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall A-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D

How much profit the business keeps from each dollar of sales and capital.

Return on equity -24.9% Better than 15%
Return on invested capital -28.7% Better than 10%
Momentum A

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -11.3% Better than 48%
6-month return 58.1% Better than 96%
12-month return (ex latest month) 173.6% Better than 98%
Distance below 52-week high 17.1% Better than 67%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 22.4x Better than 98%
Debt to assets 0.4% Better than 96%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 54.9% Better than 69%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -9.06%
1M +21.14%
3M -8.63%
6M +57.92%
YTD +216.10%
1Y +254.98%
3Y +693.87%
5Y +529.04%

Key statistics

Price & volume

Prev close
97.57
Open
95.86
Day range
93.30 - 97.24
Avg price
95.11
Volume
1.98M
Turnover
188.03M
Amplitude
4.03%
52-week range
25.23 - 115.52

Valuation

P/E
-51.79
P/E (TTM)
-45.19
P/B
5.44
EPS
-1.85
Net profit
-125.47M
Net assets
1.20B

Share structure

Market cap
6.50B
Float cap
5.61B
Shares out
67.82M
Float shares
58.60M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 78% of range
25.23 115.52

17.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-54.91M net over the window

Short interest

Shares short
6.46M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Oruka Therapeutics (ORKA)?

Oruka Therapeutics last traded at 95.81. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Oruka Therapeutics's market cap?

About 6.50B.

What is the P/E ratio of Oruka Therapeutics?

The trailing twelve-month P/E is -45.19. The Valuation tab shows it against the stock's own five-year range.

Does Oruka Therapeutics pay a dividend?

Oruka Therapeutics does not currently pay a regular dividend.

Is Oruka Therapeutics a buy according to analysts?

The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 148.44, which implies 54.9% upside from the current price. This is not investment advice.

What is Oruka Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Oruka Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.

Oruka Therapeutics discussion 0 comments

Add a comment